Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corp (Nasdaq: CTSO) on October 6, 2022, reporting events occurring on September 30, 2022. The filing addresses a significant change in executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Executive Departure: Ms. Kathleen P. Bloch notified the Board of Directors on September 30, 2022, of her decision to retire as Chief Financial Officer.
- Effective Date: Her retirement is effective as of March 31, 2023.
- Transition Plan: Ms. Bloch will assist the Company in transitioning to a replacement CFO and is expected to enter into a limited-capacity consulting arrangement following her retirement.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the planned consulting arrangement and the transition process. Management cautions that actual events may differ materially from these expectations due to risks detailed in the Company's Annual Report on Form 10-K (filed March 10, 2022) and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the official press release (Exhibit 99.1) for the formal announcement of the CFO retirement.
- Monitor subsequent filings for the appointment of a new Chief Financial Officer.
- Review the terms of the proposed consulting agreement once finalized.
- Check the Company's Form 10-K and 10-Q filings for broader operational risks that may impact the transition.